Search Results

October 25, 2026

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer

Responses were deep and durable, with 65% ongoing at clinical cutoff Results support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line Phase 3 study Data highlight the role of dual-targeting EGFR and MET, key drivers of tumor growth and resistance seen in 80 to 90 percent of HNSCC

Innovative Medicine

October 24, 2026

Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer

· New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ADT compared with immediate surgery · Twice as many patients remained free from subsequent treatment at three years with perioperative apalutamide plus ADT compared with surgery alone · Results evaluated outcomes versus surgery alone, building on the primary results presented at ASCO 2026

Innovative Medicine

October 23, 2026

Johnson & Johnson advances the next generation of solid tumor therapies with new data at ESMO 2026

· First readout following acquisition of the RIPTAC™ platform shows promising anti-tumor activity with JNJ-6143, a novel oral investigational molecule, in difficult-to-treat prostate cancer · New first-line head and neck cancer data highlight the potential of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) and its dual EGFR-MET approach, building on the established role of RYBREVANT®-based regimens in lung cancer · New ERLEADA® (apalutamide) substudy findings in prostate cancer build on the primary results presented at ASCO 2026

Innovative Medicine

October 22, 2026

Johnson & Johnson showcases breadth of rheumatology innovation at ACR Convergence 2026 with 43 presentations, including late-breaking data on ICOTYDE® (icotrokinra) in psoriatic arthritis

Patient data from the Phase 2 study of nipocalimab in Sjögren’s disease identify improvements in most core patient-relevant symptoms, with associated improvements in health-related quality of life Positive Phase 2 data support continued development of nipocalimab in systemic lupus erythematosus; Phase 3 study is recruiting

Neuroscience

October 20, 2026

Beyond discharge: why continuing care matters in schizophrenia

Neuroscience

October 20, 2026

Más allá del alta hospitalaria: por qué es importante continuar con la atención de la esquizofrenia

Innovative Medicine

October 19, 2026

Johnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn’s disease with perianal fistula

· TREMFYA maintained combined fistula remission through Week 48 across both maintenance dose regimens, including an increase from 28% at Week 24 to 35% at Week 48 in the 100 mg dose group · These findings build on the Phase 3 clinical program, demonstrating efficacy in a dedicated, randomized, placebo-controlled trial in patients with this debilitating and challenging manifestation of Crohn’s disease

Innovative Medicine

October 13, 2026

New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn’s disease patient subgroups

· New prespecified analyses showed consistent findings across clinically important and difficult to treat subgroups, including patients with prior biologic exposure · Findings build on first positive results where TREMFYA achieved combined fistula remission rates of up to 28% across dosing groups · Results come from the first dedicated Phase 3 randomized, placebo-controlled trial in adults managing Crohn’s disease with perianal fistula in more than 20 years

Innovative Medicine

October 13, 2026

TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn’s disease

· New long-term data showed clinical remission rates of up to 94% and endoscopic remission rates of up to 61% in adults with moderately to severely active Crohn’s disease · 88% of patients achieved 90-day corticosteroid-free clinical remission

Innovative Medicine

September 25, 2026

Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study

· Topline results show TREMFYA met the primary and major secondary endpoints of axial involvement in PsA - including spinal pain and stiffness - and demonstrated significant improvement in MRI-confirmed inflammation · First-ever study to use objective MRI assessments to confirm presence of axial involvement and demonstrate axial inflammation reduction in PsA

Search Results

No Results

Search Results

You are now leaving jnj.com/innovativemedicine